CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced the approval of their new Aprepitant Injection by China’s National Medical Products Administration, designed to prevent nausea and vomiting in chemotherapy patients. The product promises higher bioavailability and a reduced risk of allergic reactions compared to existing treatments, marking the seventh nanotechnology-based product in the company’s expanding cancer treatment portfolio.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
